VolitionRx Limited (NYSE American: VNRX) has announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, a development that could significantly impact the field of cancer diagnostics. The technology is reported to be the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA), overcoming a longstanding challenge in liquid biopsy by effectively separating cancer-derived DNA from the overwhelming background of healthy cell-free DNA. This capability creates highly enriched tumor DNA datasets, which are essential for accurate cancer detection and monitoring.
The implications of this announcement are substantial. Volition estimates that the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications. These figures underscore the potential commercial value of the technology and its relevance to improving cancer outcomes. The publication details a two-step process that combines physical sample enrichment with bioinformatic filtering to achieve greater than 99% pure ctDNA sequencing datasets. Early validation studies have demonstrated strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers. Additional blinded studies have produced encouraging findings, suggesting the technology's robustness and potential clinical utility.
Volition is now advancing larger validation studies, collaborating with oncology key opinion leaders, and expanding patent protection for the technology as it explores commercialization opportunities. The company is also conducting technical evaluations with potential licensing partners. This progress indicates that the technology is moving from the research phase toward potential clinical application, which could eventually provide a non-invasive tool for early cancer detection and treatment monitoring.
The peer-reviewed publication marks a critical milestone for Volition, as it provides external validation of the technology's efficacy. For the broader medical community, this development offers hope for more sensitive and specific liquid biopsy tests that could lead to earlier cancer diagnosis and better patient management. By addressing the challenge of isolating rare tumor DNA from abundant healthy DNA, Capture-Seq could enable more reliable detection of cancer at earlier stages, when treatment is more likely to be successful. This aligns with Volition's mission to save lives and improve outcomes for people with life-altering diseases through earlier detection and monitoring.
For more information, visit the company's website at Volition. To view the full press release, visit https://ibn.fm/nuJEs.
